Ann: Annual Report to shareholders , page-2

Dear BTA Holders
Interesting comment:

"Biota is confident that laninamivir is a product with many patient attributes and with value that can be realised to the benefit
of shareholders. We continue to negotiate with prospective licensees and along with our co-owner Daiichi Sankyo, to explore other options capable of delivering value.

We will continue to keep shareholders updated to the extent possible, during sensitive commercialisation negotiations."

Regards
Kangaroo1